Obermatt
See Similar Stocks →

Flags

Financial distress

MedinCell

PAR:MEDCL · FR0004065605
PharmaceuticalsSmall

360

32
Profit price95
Owner Earnings Yield1
Dividend Yield1
Price/Sales12
EV / Gross Profit5
Price/Book100
Returns on capital13
EBIT Margin9
Gross Profitability78
Accruals76
Owner Earnings Margin14
Sales growth88
Profit growth27
Reinvestment4
Price momentum86
Debt load3
Refinancing33
Debt Payback1
Liquidity27
Analyst ratings100
Opinion Changes14
Price Target Upside28
Market mood45
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MedinCell clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryFrance
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded2003
Employees142
Websitemedincell.com
ISINFR0004065605
Last UpdateApr 2, 2026
Indices
CAC All (France)SBF 120 (France)
Themes
Infectious DiseasesPsychiatryPain ManagementInflammationNeurologyCentral Nervous SystemPharmaceutical

Description

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. Business Segments The company operates primarily in the pharmaceutical sector, focusing on the research, development, and manufacturi…

Analysis

Middle-of-the-road

MedinCell S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 7/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
34
2023202420252026

All-time high

53

Mar 2026

All-time low

4

Jan 2023

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
5
16
34
Price/Earnings
100
1
100
68
Price/Book
100
100
100
100
Dividend Yield
1
1
1
1
Value (overall)
68
22
41
56

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MedinCell with its peers
Lavipharm
ATH:LAVI
44
CountryLuxembourg
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Valneva
PAR:VLA
21
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
PolyPid
NAQ:PYPD
26
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Pharvaris
NSQ:PHVS
38
CountryNetherlands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Oculis Holding
NMQ:OCS
18
CountrySwitzerland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Mediwound
NMQ:MDWD
25
CountryIsrael
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →